Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Global Clinical Professionals

Neither a doctor nor a teaching hospital

Research payments

$1,051,825

56 payments

Through program year 2025, Global Clinical Professionals is reported as receiving $1,051,825 in research payments, across 56 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $27,277 43
2024 Research $62,324 5
2022 Research $121 2
2021 Research $6,304 5
2019 Research $955,800 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amneal Pharmaceuticals LLC $955,800 1 payment
  2. Invivyd Inc $60,387 3 payments
  3. Boehringer Ingelheim International GmbH $29,213 45 payments
  4. Pfizer Inc. $6,425 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study to Evaluate the Cumulative Skin Irritation and Sensitization Potential of a Generic Norelgestromin and Ethinyl Estradiol Transdermal System 15035 mcg per day to that of Xulane Transdermal System in Normal Healthy Adult Human Female Subjects under Fasting Conditions $955,800 1 payment
  2. Canopy $60,387 3 payments
  3. A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis $22,751 19 payments
  4. An Interventional Efficacy and Safety Phase 23 Doubleblind 2Arm Study to Investigate Orally Administered Pf07321332ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Increased Risk of Progressing to Severe Illness $5,502 2 payments
  5. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $4,525 24 payments
  6. BI 456906 in NASH F2/F3 - pivotal trial $968 1 payment
  7. BI 456906 in NASH F4 - pivotal trial $968 1 payment
  8. A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $881 4 payments
  9. A Phase 1 Openlabel Nonrandomized Study to Investigate the Safety and PK Following Multiple Oral Doses of Pf07321332 Nirmatrelvirritonavir in Adult Participants With Covid19 and Severe Renal Impairment Either on Hemodialysis Or Not on Hemodialysis $42 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record